STOCK TITAN

Galera Therapeutics Inc - GRTX STOCK NEWS

Welcome to our dedicated news page for Galera Therapeutics (Ticker: GRTX), a resource for investors and traders seeking the latest updates and insights on Galera Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Galera Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Galera Therapeutics's position in the market.

Rhea-AI Summary
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced financial results for Q4 and year 2023, focusing on avasopasem and rucosopasem development. The company is evaluating strategic options to maximize shareholder value, including potential dissolution. Recent updates include workforce reduction, engagement of financial advisor, and FDA interactions. Financially, R&D expenses decreased, net loss improved, and cash reserves support operations into Q2 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.79%
Tags
-
Rhea-AI Summary
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced the need for a new trial for avasopasem, leading to the discontinuation of GRECO trials with rucosopasem. They are exploring strategic options to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
-
Rhea-AI Summary
Galera Therapeutics, Inc. will need to conduct a new Phase 3 trial for avasopasem for radiotherapy-induced severe oral mucositis (SOM) as the previous trials did not meet FDA requirements. The company has decided to discontinue both the Phase 2b GRECO-2 trial for rucosopasem in pancreatic cancer and the Phase 1/2 GRECO-1 trial for rucosopasem in lung cancer. Galera is exploring strategic alternatives to maximize shareholder value. The company's cash balance as of September 30, 2023, was $28.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.03%
Tags
none
Rhea-AI Summary
Galera Therapeutics schedules Type A Meeting with FDA regarding Complete Response Letter for avasopasem manganese
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
Rhea-AI Summary
Galera Therapeutics CEO to participate in fireside chat at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
conferences
-
Rhea-AI Summary
Galera Therapeutics, Inc. received a Complete Response Letter from the FDA for avasopasem, but intends to request a Type A meeting to discuss potential next steps. The company's cash runway has been extended into Q2 2024. Enrollment in GRECO trials with rucosopasem is ongoing. FDA granted orphan drug designation to rucosopasem for pancreatic cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.83%
Tags
Rhea-AI Summary
Galera Therapeutics receives Complete Response Letter from FDA regarding avasopasem NDA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-83.93%
Tags
none
-
Rhea-AI Summary
Galera Therapeutics presents data from the Phase 3 ROMAN trial demonstrating avasopasem's improvement in kidney function and reduction in cisplatin-related chronic kidney disease (CKD) in patients with head and neck cancer (HNC). The data also show a significant reduction in severe oral mucositis (SOM) in these patients. The avasopasem New Drug Application (NDA) is currently under priority review with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.38%
Tags
Rhea-AI Summary
Galera Therapeutics announces financial results for Q1 2023 and recent corporate updates, including FDA priority review for avasopasem NDA and $30 million raised in direct offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
Galera Therapeutics Inc

Nasdaq:GRTX

GRTX Rankings

GRTX Stock Data

8.64M
41.94M
20.14%
19.1%
3.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Malvern

About GRTX

galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.